Metropolitan Life Insurance Co NY Sells 746 Shares of NeoGenomics, Inc. (NASDAQ:NEO)
Other hedge funds have also recently modified their holdings of the company. Harbor Investment Advisory LLC bought a new stake in shares of NeoGenomics in the 3rd quarter valued at about $55,000. Destiny Wealth Partners LLC bought a new position in NeoGenomics in the 3rd quarter valued at about $65,000. Archer Investment Corp raised its holdings in NeoGenomics by 37.1% in the 3rd quarter. Archer Investment Corp now owns 1,350 shares of the medical research company’s stock valued at $65,000 after acquiring an additional 365 shares during the period. James Investment Research Inc. raised its holdings in NeoGenomics by 47.5% in the 3rd quarter. James Investment Research Inc. now owns 1,550 shares of the medical research company’s stock valued at $75,000 after acquiring an additional 499 shares during the period. Finally, HighMark Wealth Management LLC raised its holdings in NeoGenomics by 8.0% in the 3rd quarter. HighMark Wealth Management LLC now owns 2,988 shares of the medical research company’s stock valued at $144,000 after acquiring an additional 221 shares during the period. 93.29% of the stock is currently owned by institutional investors.
Several research firms have weighed in on NEO. SVB Leerink lowered their price target on shares of NeoGenomics from $50.00 to $45.00 and set an “outperform” rating on the stock in a report on Wednesday, January 12th. Needham & Company LLC lowered their price target on shares of NeoGenomics from $48.00 to $41.00 and set a “buy” rating on the stock in a report on Tuesday, December 7th. Stephens lowered their price target on shares of NeoGenomics from $60.00 to $53.00 and set an “overweight” rating on the stock in a report on Friday, November 5th. Zacks Investment Research raised shares of NeoGenomics from a “sell” rating to a “hold” rating in a report on Wednesday, January 12th. Finally, Cowen started coverage on shares of NeoGenomics in a research report on Thursday, December 16th. They set an “outperform” rating and a $42.00 target price on the stock. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $49.89.
Shares of NASDAQ:NEO opened at $18.72 on Wednesday. The company has a quick ratio of 7.42, a current ratio of 7.66 and a debt-to-equity ratio of 0.47. The firm has a market cap of $2.30 billion, a PE ratio of 52.00 and a beta of 0.63. The company’s 50 day moving average price is $26.22 and its two-hundred day moving average price is $37.30. NeoGenomics, Inc. has a 12-month low of $18.61 and a 12-month high of $55.97.
In related news, insider Douglas Matthew Brown sold 33,334 shares of the stock in a transaction that occurred on Friday, November 26th. The shares were sold at an average price of $36.85, for a total value of $1,228,357.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Mark Mallon acquired 17,000 shares of the company’s stock in a transaction that occurred on Monday, December 6th. The stock was bought at an average cost of $30.63 per share, with a total value of $520,710.00. The disclosure for this purchase can be found here. Company insiders own 4.70% of the company’s stock.
NeoGenomics Company Profile
NeoGenomics, Inc is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups.
Featured Articles
- Get a free copy of the StockNews.com research report on NeoGenomics (NEO)
- Hit the Buy Button on These 3 Oversold Tech Stocks
- It’s Time To Shut The Door On Masonite International
- Pfizer Stock is Ready to be Added to Your Portfolio
- The Purely Technical Reason Oil Will Hit $122
- 4 Best 5G Stocks to Invest in
Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO).
Receive News & Ratings for NeoGenomics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NeoGenomics and related companies with MarketBeat.com’s FREE daily email newsletter.
Original Source